{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:30:54Z","timestamp":1788546654378,"version":"build-2803163510"},"reference-count":30,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Cancer"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Epidermal growth factor receptor (EGFR) mutations are key drivers in a significant portion of non\u2010small\u2010cell lung cancer (NSCLC) patients. While third\u2010generation EGFR\u2010tyrosine kinase inhibitors (TKIs) such as osimertinib have demonstrated efficacy, the management of patients who continue to experience disease progression during treatment remains challenging. The emergence of drug resistance, including the development of secondary mutations, necessitates exploration of alternative treatment strategies. This study aims to evaluate and observe the efficacy and safety of almonertinib combined with anlotinib in patients after cancer progression during third\u2010generation EGFR\u2010TKI therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective analysis, we included EGFR\u2010mutated NSCLC patients who were resistant to third\u2010generation EGFR\u2010TKIs. All patients were treated with almonertinib combined with anlotinib. The clinical characteristics, treatment history, clinical benefits, and adverse events of these patients were retrospectively collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 16 eligible patients were included in the analysis. The results revealed that combination therapy with almonertinib and anlotinib was effective in this patient cohort. The overall response rate was 25% and the disease control rate was 93.75%. The 6 and 12\u2009months of PFS rates were 92.9% (95% confidence interval [CI] 80.3%, 100.0%) and 84.4% (95% CI 66.6%, 100.0%), respectively. Moreover, this combination therapy was generally well\u2010tolerated, with manageable adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our retrospective analysis suggests that almonertinib and anlotinib combination therapy may represent a viable option for EGFR\u2010mutated NSCLC patients who have progressed on third\u2010generation EGFR\u2010TKIs, especially for those with posterior lines and no standard treatment options. Further investigation and larger clinical trials are warranted to validate these observations and refine treatment guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1759-7714.15399","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T04:19:01Z","timestamp":1720671541000},"page":"1757-1763","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy of almonertinib and anlotinib combination therapy for advanced non\u2010small\u2010cell lung cancer patients who continued to experience cancer progression during third\u2010generation <scp>EGFR\u2010TKI<\/scp> treatment: a retrospective study"],"prefix":"10.1111","volume":"15","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Lung Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center of Cancer, Tianjin Lung Cancer Center  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center of Cancer, Tianjin Lung Cancer Center  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center of Cancer, Tianjin Lung Cancer Center  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3191-2272","authenticated-orcid":false,"given":"Meng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center of Cancer, Tianjin Lung Cancer Center  Tianjin China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30958-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00917-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113959"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5270"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023712"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14141"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S174623"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.001"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S246000"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3039"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106668"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35962-x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1542"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDY424.063"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.278"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.2969"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0399"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0591"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01585"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3563"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0454-2"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx705"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.06.017"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2021.08.2128"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0715"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.639892"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2019.09.35"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13909"}],"container-title":["Thoracic Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1759-7714.15399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T10:10:04Z","timestamp":1723543804000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.15399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":30,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1111\/1759-7714.15399"],"URL":"https:\/\/doi.org\/10.1111\/1759-7714.15399","archive":["Portico"],"relation":{},"ISSN":["1759-7706","1759-7714"],"issn-type":[{"value":"1759-7706","type":"print"},{"value":"1759-7714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"2024-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}